ADAGENE INC - ADS, EACH REPRESENTING 1.25
ADAGENE INC - ADS, EACH REPRESENTING 1.25
Hinterlegungsschein · US0053291078 · ADAG · A2QN45 (XNAS)
Übersicht
1,99 USD
8,15 % 0,15 USD
NASDAQ (XNAS) · Aktuelle Kurse und Charts bei MoneyPeak
06.06.2025 19:59

Aktuelle Kurse von ADAGENE INC - ADS, EACH REPRESENTING 1.25

BörseTickerWährungLetzter UmsatzKursTagesveränderung
XNAS: NASDAQ
NASDAQ
ADAG
USD
06.06.2025 19:59
1,99 USD
1,76 USD
+13,07 %

Performance

Heute Woche Monat 3 Monate 6 Monate 1 Jahr 5 Jahre
0,00 % 2,58 % 24,37 % -3,86 % -3,16 % -33,22 % -93,36 %

Firmenprofil zu ADAGENE INC - ADS, EACH REPRESENTING 1.25 Hinterlegungsschein

Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.

Unternehmensdaten

Name ADAGENE INC - ADS, EACH REPRESENTING 1.25
Firma Adagene Inc.
Symbol ADAG
Website https://www.adagene.com
Heimatbörse XNAS NASDAQ
WKN A2QN45
ISIN US0053291078
Wertpapierart Hinterlegungsschein
Sektor Healthcare
Branche Biotechnology
CEO Dr. Peter P. Luo Ph.D.
Marktkapitalisierung 54 Mio
Land China
Währung USD
Mitarbeiter 0,1 T
Adresse Building C14, 215123 Suzhou
IPO Datum 2021-02-09

Ticker Symbole

Name Symbol
Frankfurt 978.F
NASDAQ ADAG

Weitere Aktien

Investoren die ADAGENE INC - ADS, EACH REPRESENTING 1.25 die halten, haben auch folgende Aktien im Depot:
FOUR SEASONS EDUCATION (CAYMAN) INC AMERICAN DEPOSITARY SHARES, EACH TWO ADSS REPRESENTING ONE ORDINARY SHARE
FOUR SEASONS EDUCATION (CAYMAN) INC AMERICAN DEPOSITARY SHARES, EACH TWO ADSS REPRESENTING ONE ORDINARY SHARE Hinterlegungsschein
ORIX CORP. 23/28 MTN
ORIX CORP. 23/28 MTN Anleihe
Die Finanzplattform MoneyPeak trackt und analysiert Investitionen und Portfolios. Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Impressum Datenschutz Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025